AbbVie reported positive topline results from the Phase 3 LUNA study of atogepant, an oral CGRP receptor antagonist, for preventing menstrual migraine in adults. Taken for seven consecutive days beginning three days before menstruation across three menstrual cycles, atogepant reduced perimenstrual migraine days by an average of 1.20 days, compared with 0.40 days for placebo, or 0.80 fewer days versus placebo (p<0.0001). The treatment also met all eight ranked secondary endpoints, covering headache burden, acute medication use, disability, cognitive function and responder outcomes. Safety was consistent with atogepant’s established profile, with no new safety signals. The 468-participant study enrolled adult female participants in Europe and Asia with pure menstrual migraine or menstrually-related migraine. AbbVie said it plans to submit the results to health authorities worldwide and present them at future medical congresses. Atogepant is approved in 60 countries and marketed as AQUIPTA in the European Union and QULIPTA in the United States, Canada, Israel and Puerto Rico. No treatment is currently approved specifically for menstrual migraine, while 66% of eligible respondents in the CaMEO-I study reported migraine attacks around menstruation.